review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Alberto Mantovani | Q22069468 |
Gordon J. Freeman | Q27088375 | ||
Paolo Antonio Ascierto | Q89457677 | ||
Katerina Politi | Q91774071 | ||
Omid Hamid | Q94947567 | ||
Robert L Ferris | Q38328358 | ||
Sandra Demaria | Q38543969 | ||
Lisa H. Butterfield | Q41520723 | ||
P2093 | author name string | Roger S Lo | |
Paul Nathan | |||
Igor Puzanov | |||
P2860 | cites work | Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance | Q27853210 |
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program | Q30746423 | ||
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Q36553576 | ||
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. | Q36617328 | ||
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | Q36730827 | ||
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia | Q37040899 | ||
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial | Q38601785 | ||
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. | Q38653551 | ||
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy | Q38704192 | ||
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. | Q38708831 | ||
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model | Q38821358 | ||
Elements of cancer immunity and the cancer-immune set point | Q39094764 | ||
Tumour-associated macrophages as treatment targets in oncology. | Q39100693 | ||
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Q39130451 | ||
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
Resistance to checkpoint blockade therapy through inactivation of antigen presentation. | Q42630391 | ||
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation | Q46418198 | ||
Tumor Mutational Burden and Response Rate to PD-1 Inhibition. | Q47270933 | ||
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer | Q47389008 | ||
IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. | Q47599849 | ||
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer | Q47652834 | ||
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Q50001757 | ||
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma | Q50207111 | ||
Understanding the tumor immune microenvironment (TIME) for effective therapy. | Q52311744 | ||
A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer. | Q52647887 | ||
Immune oncology, immune responsiveness and the theory of everything. | Q55487467 | ||
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | Q57069952 | ||
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy | Q57472982 | ||
Macrophage Checkpoint Blockade in Cancer - Back to the Future | Q58083703 | ||
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma | Q58083758 | ||
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial | Q58599459 | ||
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA | Q58700455 | ||
Tumor mutational load predicts survival after immunotherapy across multiple cancer types | Q62745707 | ||
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy | Q89352753 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P433 | issue | 1 | |
P921 | main subject | immunotherapy | Q1427096 |
P304 | page(s) | 221 | |
P577 | publication date | 2019-08-15 | |
P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
P1476 | title | The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 | |
P478 | volume | 7 |